SHENZHEN, China–(BUSINESS WIRE)–Het merk voor technologie-accessoires aulumu introduceert de A18 Series voor iPhone 18, een nieuwe collectie smartphonehoesjes ontworpen rond vederlichte bescherming, innovatief materiaal en sublieme visuele afwerkingen. Het assortiment omvat de A18 Armor Shockproof Aramid Fiber Case, twee ultradunne modellen in aramidevezel, de Ghost Lumen Transparent Case en de Particle Vegan Leather Case. De A18 Armor, de blikvanger van de collectie, combineert 1500D aramide
Month: September 2026
SHENZHEN, Chine–(BUSINESS WIRE)–La marque d’accessoires technologiques aulumu lance la gamme A18 pour iPhone 18, une nouvelle collection de coques pour smartphone conçue pour allier protection légère, matériaux innovants et finitions visuelles distinctives. La gamme comprend les modèles A18 Armor Shockproof Aramid Fiber Case, A18 Ultra-Slim Gradient Aramid Fiber Case, A18 Ultra-Slim Pixel Aramid Fiber Case, A18 Ghost Lumen Transparent Case et A18 Particle Vegan Leather Case. Pièce maîtresse d
SHENZHEN, China–(BUSINESS WIRE)–Technology accessories brand aulumu has introduced the A18 Series for iPhone 18, a new collection of smartphone cases designed around lightweight protection, material innovation and distinctive visual finishes. The range includes the A18 Armor Shockproof Aramid Fiber Case, two ultra-slim aramid fibre models, the Ghost Lumen Transparent Case, and the Particle Vegan Leather Case. At the centre of the collection, the A18 Armor combines 1500D aramid fibre and therm
SHENZHEN, Cina–(BUSINESS WIRE)–Il marchio di accessori tecnologici aulumu ha presentato la A18 Series per iPhone 18, una nuova collezione di custodie per smartphone progettate per garantire una protezione leggera, innovazione nei materiali e look raffinati. La gamma comprende la custodia A18 Armor Shockproof Aramid Fiber Case, due modelli ultrasottili in fibra aramidica, la custodia Ghost Lumen Transparent Case e la custodia Particle Vegan Leather Case. Al centro della collezione, A18 Armor a
SHENZHEN, China–(BUSINESS WIRE)–La marca de accesorios tecnológicos aulumu ha presentado la serie A18 para el iPhone 18, una nueva colección de fundas para smartphones diseñadas pensando en la protección ligera, la innovación en los materiales y unos acabados visuales distintivos. La gama incluye la A18 Armor Shockproof Aramid Fiber Case, dos modelos ultradelgados de fibra de aramida, la Ghost Lumen Transparent Case y la Particle Vegan Leather Case. Como pieza central de la colección, A18 Arm
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF – April 09.09.2026 FAPR.LN IE000WX2HZQ7 250,002.00 USD 6,539,127.94 26.156
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF – July 09.09.2026 FJUL.LN IE000YJBT6I5 100,002.00 USD 2,922,764.14 29.227
CANTON, Mass.–(BUSINESS WIRE)–Pecos County Memorial Hospital District (Fort Stockton, TX), a Critical Access Hospital serving the residents of rural West Texas, has announced its transition to a unified MEDITECH Expanse EHR using MEDITECH as a Service (MaaS). The cloud-native platform will replace the hospital’s current fragmented software landscape, which includes separate systems for the acute, emergency department, and ambulatory settings. “Expanse supports our mission to improve the quali
Company will hold a formal presentation and one-on-one investor meetings September 14-16, 2026
ISFIYA, Israel and LAS VEGAS, Sept. 10, 2026 (GLOBE NEWSWIRE) — MBody AI Ltd. (“MBody AI” or the “Company”) (NASDAQ: MBAI) today announced that John Fowler, Chief Executive Officer and Tim Hayden, Chief Financial Officer of MBody AI, will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.
In addition to the formal presentation which will be available On-Demand, management will be available for one-on-one investor meetings during the conference. Investors interested in scheduling a one-on-one meeting with management during the conference should contact their H.C. Wainwright representative or meetings@hcwco.com or Lytham Partners at 602-889-9700 or ir@mbody.ai.
MBody AI’s Orchestrator is a proprietary, hardware-agnostic software platform that serves as an intelligence layer designed to enable autonomous systems to operate, coordinate, and improve more effectively than they otherwise would in real-world physical environments. It is designed as a full-stack embodied AI software system that integrates multiple functional components intended to support autonomous operation and fleet-level coordination.
The two core features of Orchestrator are AI Optimization, Task Verification and Reporting. AI Optimization uses artificial intelligence to assess telemetry and run-time data and generate recommendations to improve performance against customer key performance indicators, across a customer’s fleet regardless of brand.
Task Verification and Reporting provides unified dashboarding and reporting across a customer’s full fleet and multiple robot types, including verification that assigned tasks have been completed.
Learn more about MBody AI’s growth trajectory at ir.mbody.ai
About H.C. Wainwright & Co.
H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory, sales & trading, research, and related services to public and private growth companies across multiple focuses and regions. The HCW team has been the leader in the CMPO (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transaction markets since 1998.
About MBody AI Ltd.
MBody AI Ltd. (NASDAQ: MBAI) develops enterprise software that deploys and manages autonomous robot workforces for hospitality and gaming operators. The Company’s proprietary MBody AI Orchestrator is a hardware-agnostic software platform that manages diverse robot fleets from multiple vendors across sites and use cases under long-term agreements. MBody AI counts Fortune 500 operators among its customers.
No Offer or Solicitation
This press release does not constitute an offer to sell or a solicitation of an offer to buy, and shall not constitute an offer, solicitation, or sale in any state, province, territory, or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements made in graphics, images, headlines, and other visual elements of this release. All statements other than statements of historical fact are forward-looking statements, which include, among others, statements regarding the expected performance, functionality, and capabilities of the MBody AI Orchestrator platform; the Company’s technology roadmap; the Company’s expectation that operational data generated by its deployments will refine its models and improve platform performance over time; the Company’s deployment pipeline, customer expansion, and commercial scaling; the anticipated growth of the embodied AI market; the Company’s ability to maintain continued compliance with Nasdaq listing requirements; and the Company’s continued qualification as a foreign private issuer. These forward-looking statements are based on the Company’s current intentions, beliefs, and expectations regarding future events. Actual results may differ materially due to risks and uncertainties including, but not limited to, the risk that the multi-brand fleet control capability does not complete testing or is not deployed with customers on the anticipated timeline or at all; the risk that the customer-systems integration capability is never completed or made available, and that the related provisional patent applications do not result in issued patents; the risk that the platform does not perform as designed or that operational data does not yield the expected improvements; customer concentration risk, the Company being substantially dependent on two enterprise customers; the Company’s ability to convert pilot deployments into contracted revenue; the risk that the Company fails to satisfy Nasdaq continued listing standards, including the minimum bid price and shareholders’ equity requirements; the risk that the Company ceases to qualify as a foreign private issuer and becomes subject to domestic reporting requirements; the Company’s need for additional capital and the dilutive effect of any financing; market conditions; and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.
Quick Facts
| Issuer: | MBody AI Ltd. (NASDAQ: MBAI) |
| Listing: | Nasdaq Capital Markets |
| Sector: | Technology |
| Industry: | Embodied AI and enterprise robotics (physical AI) |
| Event: | H.C. Wainwright 28th Annual Global Investment Conference |
| Date: | September 14-16, 2026 |
| Location: | Lotte New York Palace Hotel, New York City |
| CUSIP | M6S83C106 |
Investor Relations:
Lytham Partners, LLC
602-889-9700
ir@mbody.ai
Media Contact:
Core IR
ir@mbody.ai
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1633c2e1-2003-4789-b023-5900f7374b46
DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City.
The SeaStar Medical presentation will be available on September 11, 2026, at 7:00 am Eastern Time and can be accessed by visiting the Events & Presentations page, located under the Investor Relations section of the SeaStar Medical website. The presentation will be available for 60 days following the event.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
IR@SEASTARMED.COM
